## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.91 indicates fundamental undervaluation. Quality metrics strong (ROE 31%). Caution: momentum weakening (-3.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($61.25)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bearish (Bullish: 2, Bearish: 7)

**1. Class Action Lawsuit Filed Against DexCom, Inc. (DXCM) - Recover Losses - Contact Levi & Korsinsky Before December 26, 2025**
- Source: ACCESS Newswire | 20251217T200833 | Bearish | Relevance: 100%
- Levi & Korsinsky, LLP has announced a class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who suffered losses due to alleged securities fraud between January 8, 2024, and September 17, 2025. The lawsuit claims DexCom made unauthorized material design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and posing health risks, which the company allegedly downplayed. Investors affected during the specified period are encouraged to contact Levi & Korsinsky to explore potential recovery.

**2. Key facts: Class action lawsuit filed against DexCom; Mizuho raises price target**
- Source: TradingView â€” Track All Markets | 20251217T200749 | Neutral | Relevance: 100%
- A class action lawsuit has been filed against DexCom, Inc. regarding alleged false statements about the safety of its G6 and G7 glucose monitoring systems. Concurrently, Mizuho has increased its price target for DexCom (DXCM) from $75.00 to $78.00 per share.

**3. Here's Why You Should Hold DexCom Stock in Your Portfolio for Now**
- Source: Finviz | 20251217T180756 | Bullish | Relevance: 100%
- DexCom, Inc. is well-positioned for growth due to the significant potential in the continuous glucose monitoring (CGM) market, strong Q3 2025 performance, and increasing adoption of its innovative product ecosystem. Despite facing stiff competition, the company's strategic initiatives and expanding market reach in diabetes management are expected to drive sustained growth. Analysts have maintained a stable estimate trend for DexCom, with expected revenue and EPS growth in the coming quarters.

**4. DexCom (DXCM): Mizuho Raises Price Target to $78, Maintains Outperform Rating | DXCM Stock News**
- Source: GuruFocus | 20251217T135920 | Bullish | Relevance: 100%
- Mizuho has increased its price target for DexCom (DXCM) to $78 from $75, while reaffirming an Outperform rating, reflecting increased analyst confidence in the company's market performance. This adjustment aligns with a trend of positive analyst ratings and upgrades for DexCom, despite some previous target reductions. DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients.

**5. SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A**
- Source: GlobeNewswire | 20251217T121500 | Bearish | Relevance: 100%
- Bernstein Liebhard LLP has filed a securities class action lawsuit against DexCom, Inc. (NASDAQ: DXCM) on behalf of investors who purchased shares between January 8, 2024, and September 17, 2025. The lawsuit alleges DexCom made misrepresentations regarding the accuracy, reliability, and functionality of its G7 continuous glucose monitoring system. Investors who lost money in DexCom securities during this period are encouraged to contact the firm to discuss their legal options, with a lead plaintiff deadline of December 26, 2025.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Mizuho | $78 | $75 | +4% |
| 2025-12-11 | Citigroup | $77 | $75 | +3% |
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Mizuho | main | Outperform |
| 2025-12-11 | Citigroup | main | Buy |
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 11.4% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +9%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.91 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Analyst sentiment positive (3 raises, avg +9%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.8B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.91 |
| Forward P/E | 26.5 |
| Current P/E | 31.8 |
| YoY Growth | 20.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 7.5% to 4.4% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 70th percentile. MRS_5 at 0.4% confirms short-term momentum alignment. Below SMA200 (0.89x), long-term trend not supportive. RSI neutral at 54. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.42% (CS: 70) | Strong |
| RSI_14 | 54.3 | Neutral |
| MACD Histogram | 0.29 | Bullish |
| vs SMA20 | 1.023x | Above |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 0.886x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $65.75
- **Stop Loss:** $61.25 (6.8% risk)
- **Target:** $74.75 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 240
- **Position Value:** $15,780.00
- **Portfolio %:** 15.78%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*